Nexalin Patent for Non-Invasive Deep-Brain Stimulation Device for Alzheimer’s and Dementia

 Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.  The newly issued patent entitled, “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method for Alzheimer’s and Dementia,” relates to the Company’s Gen-2 and Gen-3 brain stimulation medical device that administers a proprietary frequency based waveform that is designed to effectively treat patients in a pain free and undetectable manner

https://www.globenewswire.com/news-release/2024/06/20/2901672/0/en/Nexalin-Technology-Awarded-Key-Patent-Related-to-its-Non-Invasive-Frequency-Based-Deep-Brain-Stimulation-Device-for-the-Treatment-of-Alzheimer-s-and-Dementia.html